Intellectual Property India Publishes Patent Application for 'A Novel Quinoline-pyrimidine Hybrid Derivatives As Selective Egfr Inhibitors For The Treatment Of Non-Small Cell Lung Cancer And Process For Their Preparation' Filed by Dr. Hemalatha K; Mr. Kumaraswamy B; and Dr. Gurubasavaraja Swamy P M

MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202641049621 A) filed by Dr. Hemalatha K; Mr. Kumaraswamy B; and Dr. Gurubasavaraja Swamy P M, Bengaluru, Karnataka, on April 18, for 'a novel quinoline-pyrimidine hybrid derivatives as selective egfr inhibitors for the treatment of non-small cell lung cancer and process for their preparation.'

Inventor(s) include Dr. Hemalatha K; Mr. Kumaraswamy B; and Dr. Gurubasavaraja Swamy P M.

The application for the patent was published on May 1, under issue no. 18/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to novel quinoline-pyrimidine hybrid derivatives designed as selective inhibitors of Epider...